Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Ophthalmology

Can Biologics Treat Severe Vernal Keratoconjunctivitis?

At a Glance

Biologic therapies like Omalizumab are sometimes used off-label to treat severe, refractory vernal keratoconjunctivitis (VKC) when standard eye drops fail. These medications block specific immune responses to reduce intense eye inflammation, but require close monitoring by specialists.

Yes, biologic therapies are sometimes used to treat severe vernal keratoconjunctivitis (VKC), but they are currently reserved for the most extreme, refractory cases where standard treatments have failed. Because there are no biologic drugs officially approved by regulatory agencies (like the FDA or EMA) specifically for VKC, their use is considered off-label [1][2].

When standard eye drops—such as topical steroids or immunomodulators like cyclosporine or tacrolimus—do not bring your or your child’s VKC under control, doctors may look to systemic (whole-body) medications [3][4][5]. Exploring biologics requires a collaborative approach, usually involving an ophthalmologist alongside an allergy or immunology specialist.

Omalizumab: The Most Studied Biologic for VKC

Omalizumab is a type of biologic medication known as a monoclonal antibody, which is administered as a regular injection. It works by binding to and blocking IgE (Immunoglobulin E), an antibody produced by the immune system that drives severe allergic reactions.

While Omalizumab is primarily approved for conditions like severe asthma and chronic hives, multiple case reports and clinical studies have shown it can be an effective off-label treatment for patients with severe, refractory VKC [1][2][6]. For those who do not respond to conventional therapies, Omalizumab has been shown to reduce intense eye inflammation, help heal the surface of the eye, and resolve symptoms [1][2][7].

Because VKC involves complex immune responses, blocking IgE appears to interrupt the cycle of severe inflammation that causes the intense itching, light sensitivity, and thick discharge characteristic of the disease [7].

Safety and Risks: Like all powerful medications, Omalizumab carries side effects. Common reactions include pain, swelling, or redness at the injection site [8]. There is also a rare but serious risk of a severe allergic reaction called anaphylaxis, which is why patients receiving this therapy are carefully monitored by medical professionals, especially during initial doses [9][10][11].

What About Dupilumab?

Patients familiar with severe allergies or eczema (atopic dermatitis) often ask about Dupilumab. This biologic, also given as an injection, blocks different inflammatory pathways (IL-4 and IL-13) and is highly effective for systemic allergic conditions.

However, there is currently a lack of evidence supporting Dupilumab as a treatment specifically for VKC [12][13]. In fact, one of the most well-documented side effects of Dupilumab is the development or worsening of eye inflammation, known as Dupilumab-associated ocular surface disease (DAOSD) [14][15][16]. Patients taking Dupilumab for eczema sometimes develop severe conjunctivitis, which in rare cases can become extreme enough to require stopping the medication [17][18]. Because of this, Dupilumab is generally not used to treat VKC, and patients with pre-existing eye conditions are at a higher risk for these eye-related side effects [19][20].

Other Systemic and Emerging Therapies

Researchers are continuing to look for ways to help patients with refractory VKC. Other options that target specific parts of the immune system include:

  • Systemic Immunomodulators: Established oral medications, such as oral cyclosporine, are sometimes used to calm the immune system from the inside out when eye drops are insufficient [21].
  • JAK Inhibitors: Newer oral medications, such as upadacitinib, are beginning to be explored for severe refractory cases [22]. These drugs work by blocking Janus kinases (JAK), which are enzymes inside cells that transmit the signals causing inflammation.
  • Targeted Biological Pathways: Researchers are studying other specific inflammatory markers in the tears and eyes (like eosinophils and TNF-α) to develop more personalized treatments in the future [23][24].

Navigating “Off-Label” Treatments

When a drug is used “off-label,” it means doctors are prescribing a medication approved for one condition to treat a different condition, based on medical evidence and clinical judgment [1][6].

If your care team suggests an off-label biologic like Omalizumab, they will carefully monitor your or your child’s progress. Because these are powerful, whole-body medications, they require continuous evaluation. It is also important to know that off-label treatments can sometimes be challenging to get covered by insurance. You may need to work closely with your doctor’s office to submit prior authorizations or appeals to your insurance company.

Common questions in this guide

Are biologics officially approved for treating VKC?
Currently, no biologic drugs are officially approved by regulatory agencies specifically for vernal keratoconjunctivitis. When doctors prescribe biologics like Omalizumab for VKC, it is considered an off-label treatment for extreme cases where standard eye drops have failed.
Can Dupilumab be used to treat severe VKC?
Dupilumab is generally not used for VKC. While it is effective for other allergic conditions like eczema, it is known to cause or worsen eye inflammation as a side effect, making it risky for patients with pre-existing ocular surface diseases.
How does Omalizumab help with severe allergic eye symptoms?
Omalizumab works by blocking IgE, an antibody that drives severe allergic reactions. By interrupting this immune response, it can reduce intense eye inflammation, help heal the eye surface, and resolve persistent symptoms in severe cases.
What should I expect if my doctor prescribes an off-label biologic?
You will require close monitoring by your medical team to evaluate the drug's effectiveness and watch for potential whole-body side effects. Because the use is off-label, you may also need to work closely with your doctor's office to get the treatment covered by insurance.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I (or my child) at the point where standard eye drops are no longer enough to control the VKC?
  2. 2.How do we safely transition from using steroid eye drops to a systemic therapy?
  3. 3.What is the process for getting insurance approval for an off-label biologic, and will your office assist with prior authorizations or appeals?
  4. 4.If we start an off-label biologic like Omalizumab, how long should we expect it to take before we see improvement in my symptoms?
  5. 5.How will we monitor for potential systemic side effects if we start a whole-body medication?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Are Cold Compresses Good for VKC Flare-Ups?Does Vernal Keratoconjunctivitis Go Away After Puberty?How Does Eye Rubbing Cause Keratoconus in VKC?How Does Vernal Keratoconjunctivitis Affect Mental Health?How to Give Eye Drops to a Light-Sensitive ChildWhat Are the Best Ways to Prevent VKC Flare-Ups?What Are the Types of Vernal Keratoconjunctivitis (VKC)?What Are the Risks of Steroid Eye Drops for VKC?What Are the Symptoms of a VKC Shield Ulcer?Is It VKC or Seasonal Allergies? Symptoms ComparedWhen to Seek Emergency Care for a VKC Flare-Up?

References

References (24)
  1. 1

    Vernal keratoconjunctivitis treated with omalizumab: A case series.

    Occasi F, Duse M, Nebbioso M, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2017; (28(5)):503-505 doi:10.1111/pai.12737.

    PMID: 28543949
  2. 2

    Clinical efficacy and safety of omalizumab in conventional treatment-resistant vernal keratoconjunctivitis: Our experience and literature review.

    Manti S, Parisi GF, Papale M, et al.

    Immunity, inflammation and disease 2021; (9(1)):3-7 doi:10.1002/iid3.384.

    PMID: 33434384
  3. 3

    Efficacy of Topical Cyclosporine 0.05% the Treatment of Vernal Keratoconjunctivitis.

    Subedi K, Sharma B, Shrestha S

    Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 2020; (12(23)):39-47 doi:10.3126/nepjoph.v12i1.24489.

    PMID: 32799238
  4. 4

    Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials.

    Zhao M, He F, Yang Y, et al.

    European journal of hospital pharmacy : science and practice 2022; (29(3)):129-133 doi:10.1136/ejhpharm-2020-002447.

    PMID: 33144336
  5. 5

    NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis.

    Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, et al.

    Clinical therapeutics 2023; (45(12)):1284-1288 doi:10.1016/j.clinthera.2023.09.022.

    PMID: 37872059
  6. 6

    Pediatric usage of Omalizumab: A promising one.

    Yu L, Zhang H, Pan J, Ye L

    The World Allergy Organization journal 2021; (14(12)):100614 doi:10.1016/j.waojou.2021.100614.

    PMID: 34963793
  7. 7

    Vernal keratoconjunctivitis: Current immunological and clinical evidence and the potential role of omalizumab.

    Doan S, Papadopoulos NG, Lee JK, et al.

    The World Allergy Organization journal 2023; (16(6)):100788 doi:10.1016/j.waojou.2023.100788.

    PMID: 37389200
  8. 8

    Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.

    Acar A, Gerceker Turk B, Ertam Sagduyu I, et al.

    Cutaneous and ocular toxicology 2020; (39(3)):249-253 doi:10.1080/15569527.2020.1787432.

    PMID: 32597235
  9. 9

    Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.

    Di Bona D, Fiorino I, Taurino M, et al.

    Respiratory medicine 2017; (130()):55-60 doi:10.1016/j.rmed.2017.07.013.

    PMID: 29206634
  10. 10

    Use of biologics in allergen immunotherapy.

    Pfützner W, Schuppe M

    Allergologie select 2021; (5()):108-118 doi:10.5414/ALX02206E.

    PMID: 33634221
  11. 11

    Omalizumab Enables Bee Venom Desensitization in Patients With Anaphylactic Reactions to Venom Immunotherapy.

    Capper K, McGettigan B, Willis C, Stevenson B

    The journal of allergy and clinical immunology. In practice 2026; (14(2)):475-481.e1 doi:10.1016/j.jaip.2025.09.038.

    PMID: 41072658
  12. 12

    Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).

    de Bruin-Weller M, Thaçi D, Smith CH, et al.

    The British journal of dermatology 2018; (178(5)):1083-1101 doi:10.1111/bjd.16156.

    PMID: 29193016
  13. 13

    Ocular complications of atopic dermatitis.

    Hsu JI, Pflugfelder SC, Kim SJ

    Cutis 2019; (104(3)):189-193.

    PMID: 31675394
  14. 14

    Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.

    Treister AD, Kraff-Cooper C, Lio PA

    JAMA dermatology 2018; (154(10)):1208-1211 doi:10.1001/jamadermatol.2018.2690.

    PMID: 30167653
  15. 15

    Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.

    Foley P, Kerdraon YA, Hogden JP, et al.

    The Australasian journal of dermatology 2022; (63(4)):421-436 doi:10.1111/ajd.13924.

    PMID: 36125089
  16. 16

    Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report.

    Adachi R, Shoji J, Hirota A, et al.

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2022; (18(1)):89 doi:10.1186/s13223-022-00727-6.

    PMID: 36184619
  17. 17

    Conjunctivitis in patients with atopic dermatitis treated with dupilumab.

    Ferreira S, Torres T

    Drugs in context 2020; (9()) doi:10.7573/dic.2020-2-3.

    PMID: 32426016
  18. 18

    Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.

    Napolitano M, Di Guida A, Fabbrocini G, Patruno C

    Dermatologic therapy 2021; (34(5)):e15059 doi:10.1111/dth.15059.

    PMID: 34241938
  19. 19

    Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.

    Achten RE, Van Luijk C, Van der Rijst L, et al.

    Acta dermato-venereologica 2022; (102()):adv00666 doi:10.2340/actadv.v102.1128.

    PMID: 35098318
  20. 20

    A risk-scoring system to predict dupilumab-associated ocular surface disease in patients with atopic dermatitis.

    Shim S, Kim JS, Yee J, Gwak HS

    Frontiers in pharmacology 2024; (15()):1425550 doi:10.3389/fphar.2024.1425550.

    PMID: 39148538
  21. 21

    Oral Cyclosporine in Vernal Keratoconjunctivitis: Indications, Outcomes, and Effect on Corticosteroid Use.

    Kate A, Tallapelly HG, Jain N, et al.

    Cornea 2025; (44(9)):1078-1083 doi:10.1097/ICO.0000000000003786.

    PMID: 39791868
  22. 22

    A Case of Refractory Vernal Keratoconjunctivitis Showing Improvement after the Administration of Upadacitinib for the Treatment of Atopic Dermatitis.

    Mima Y, Tsutsumi E, Ohtsuka T, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(12)) doi:10.3390/diagnostics14121272.

    PMID: 38928687
  23. 23

    Conjunctival transcriptome analysis reveals the overexpression of multiple pattern recognition receptors in vernal keratoconjunctivitis.

    Leonardi A, Daull P, Garrigue JS, et al.

    The ocular surface 2021; (19()):241-248 doi:10.1016/j.jtos.2020.09.009.

    PMID: 33098984
  24. 24

    [Current aspects of vernal and atopic keratoconjunctivitis].

    Messmer EM, Priglinger SG, Kassumeh S

    Die Ophthalmologie 2024; (121(3)):173-179 doi:10.1007/s00347-024-01984-z.

    PMID: 38334798

This page provides educational information about off-label biologic treatments for VKC. It does not replace professional medical advice; always consult your ophthalmologist or immunologist regarding systemic therapies.

Get notified when new evidence is published on Vernal keratoconjunctivitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.